Latest Blog Posts Tagged "Neuroprotective/Regenerative"
February 28, 2017
Jazz Pharmaceuticals recently announced a Phase II trial to test a therapy for excessive daytime sleepiness in people with Parkinson's disease.
October 20, 2016
Members of the MJFF Patient Council will participate in a pilot to develop and test a method to integrate patient preferences on benefits and risks into trials.
September 01, 2016
MJFF-funded trial evaluating a novel therapy to treat Parkinson's disease dementia is actively recruiting.
August 24, 2016
To keep you informed of the Foundation's research investments, we're highlighting a few newly funded grants supporting the development of therapies to address common non-motor symptoms of Parkinson's.
December 28, 2015
In this blog, we highlight research progress in 2015 and look forward to accomplishments in 2016.
December 28, 2015
Adamas has announced positive Phase III results for its treatment for dyskinesia, involuntary movements that are a side effect of levodopa use. Such a therapy could impact how we treat motor symptoms.
December 14, 2015
Mark Frasier, PhD, Senior Vice President of Research Programs at MJFF, discusses Parkinson's disease research highlights from 2015.
March 12, 2015
Following Monday's announcement of Apple's ResearchKit and MJFF's Fox Insight online study, news outlets around the web are chiming in about technology's impact on medical research.
March 09, 2015
In conjunction with Apple's announcement of ResearchKit, MJFF is announcing the launch of Fox Insight, a Web-based virtual clinical study open to individuals of any age, both with and without PD.
December 16, 2014
Biotech AFFiRiS has begun a clinical trial for a new vaccine (PD03A) to treat Parkinson's. This builds on the success of the MJFF-funded trial of the company's first PD vaccine candidate (PD01A).